Title:
METHODS FOR TREATING DIABETES AND METHODS FOR REDUCING BODY WEIGHT
Document Type and Number:
Japanese Patent JP2015044831
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide compositions for reducing body weight while keeping lean tissue in patients suffering from diabetes.SOLUTION: A pharmaceutical composition containing poly(lactide-co-glycolide) copolymer and exendin-4 (SEQ ID NO:1) is administered to achieve a mean steady state plasma concentration of exendin-4 of 170-600 pg/ml for at least one month. Preferably, the pharmaceutical composition contains 93%(w/w) of poly(lactide-co-glycolide) copolymer and 5%(w/w) of exendin-4.
Inventors:
MARK FINEMAN
LEIGH MACCONELL
KRISTIN TAYLOR
LEIGH MACCONELL
KRISTIN TAYLOR
Application Number:
JP2014210957A
Publication Date:
March 12, 2015
Filing Date:
October 15, 2014
Export Citation:
Assignee:
AMYLIN PHARMACEUTICALS LLC
ASTRAZENECA PHARMACEUTICALS LP
ASTRAZENECA PHARMACEUTICALS LP
International Classes:
A61K38/00; A61K47/26; A61K47/34; A61P3/04; A61P3/10
Domestic Patent References:
| JP2002544127A | 2002-12-24 | |||
| JP2002544127A | 2002-12-24 |
Other References:
JPN5008012860; ＧＥＤＵＬＩＮ Ｂ Ｒ: ＤＩＡＢＥＴＯＬＯＧＩＡ Ｖ４８ Ｎ７, 200507, Ｐ１３８０-１３８５
JPN7011001835; ＢＵＳＥ，Ｊ．Ｂ． ｅｔ ａｌ: 'Ｅｆｆｅｃｔｓ ｏｆ ｅｘｅｎａｔｉｄｅ （ｅｘｅｎｄｉｎ-４） ｏｎ ｇｌｙｃｅｍｉｃ ｃｏｎｔｒｏｌ ｏｖｅｒ ３０ ｗｅｅｋｓ ｉｎ ｓｕｌｆｏｎｙｌｕｒｅａ-ｔｒｅａｔｅｄ ｐａｔｉｅｎｔｓ' Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｖｏｌ．２７， Ｎｏ．１１, 2004, ｐ．２６２８-３５
JPN5008012862; 'ＥＸＥＮＡＴＩＤＥ： ＡＣ ２９９３， ＡＣ００２９９３， ＡＣ２９９３Ａ， ＥＸＥＮＤＩＮ ４， ＬＹ２１４８５６８' ＤＲＵＧＳ ＩＮ Ｒ ＆ Ｄ Ｖ５ Ｎ１, 2004, Ｐ３５-４０, ＡＤＩＳ ＩＮＴＥＲＮＡＴＩＯＮＡＬ
JPN7011001837; Ａｍｙｌｉｎ Ｐｒｅｓｓ Ｒｅｌｅａｓｅ , 2004
JPN5008012860; ＧＥＤＵＬＩＮ Ｂ Ｒ: ＤＩＡＢＥＴＯＬＯＧＩＡ Ｖ４８ Ｎ７, 200507, Ｐ１３８０-１３８５
JPN7011001835; ＢＵＳＥ，Ｊ．Ｂ． ｅｔ ａｌ: 'Ｅｆｆｅｃｔｓ ｏｆ ｅｘｅｎａｔｉｄｅ （ｅｘｅｎｄｉｎ-４） ｏｎ ｇｌｙｃｅｍｉｃ ｃｏｎｔｒｏｌ ｏｖｅｒ ３０ ｗｅｅｋｓ ｉｎ ｓｕｌｆｏｎｙｌｕｒｅａ-ｔｒｅａｔｅｄ ｐａｔｉｅｎｔｓ' Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｖｏｌ．２７， Ｎｏ．１１, 2004, ｐ．２６２８-３５
JPN5008012862; 'ＥＸＥＮＡＴＩＤＥ： ＡＣ ２９９３， ＡＣ００２９９３， ＡＣ２９９３Ａ， ＥＸＥＮＤＩＮ ４， ＬＹ２１４８５６８' ＤＲＵＧＳ ＩＮ Ｒ ＆ Ｄ Ｖ５ Ｎ１, 2004, Ｐ３５-４０, ＡＤＩＳ ＩＮＴＥＲＮＡＴＩＯＮＡＬ
JPN7011001837; Ａｍｙｌｉｎ Ｐｒｅｓｓ Ｒｅｌｅａｓｅ , 2004
JPN7011001835; ＢＵＳＥ，Ｊ．Ｂ． ｅｔ ａｌ: 'Ｅｆｆｅｃｔｓ ｏｆ ｅｘｅｎａｔｉｄｅ （ｅｘｅｎｄｉｎ-４） ｏｎ ｇｌｙｃｅｍｉｃ ｃｏｎｔｒｏｌ ｏｖｅｒ ３０ ｗｅｅｋｓ ｉｎ ｓｕｌｆｏｎｙｌｕｒｅａ-ｔｒｅａｔｅｄ ｐａｔｉｅｎｔｓ' Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｖｏｌ．２７， Ｎｏ．１１, 2004, ｐ．２６２８-３５
JPN5008012862; 'ＥＸＥＮＡＴＩＤＥ： ＡＣ ２９９３， ＡＣ００２９９３， ＡＣ２９９３Ａ， ＥＸＥＮＤＩＮ ４， ＬＹ２１４８５６８' ＤＲＵＧＳ ＩＮ Ｒ ＆ Ｄ Ｖ５ Ｎ１, 2004, Ｐ３５-４０, ＡＤＩＳ ＩＮＴＥＲＮＡＴＩＯＮＡＬ
JPN7011001837; Ａｍｙｌｉｎ Ｐｒｅｓｓ Ｒｅｌｅａｓｅ , 2004
JPN5008012860; ＧＥＤＵＬＩＮ Ｂ Ｒ: ＤＩＡＢＥＴＯＬＯＧＩＡ Ｖ４８ Ｎ７, 200507, Ｐ１３８０-１３８５
JPN7011001835; ＢＵＳＥ，Ｊ．Ｂ． ｅｔ ａｌ: 'Ｅｆｆｅｃｔｓ ｏｆ ｅｘｅｎａｔｉｄｅ （ｅｘｅｎｄｉｎ-４） ｏｎ ｇｌｙｃｅｍｉｃ ｃｏｎｔｒｏｌ ｏｖｅｒ ３０ ｗｅｅｋｓ ｉｎ ｓｕｌｆｏｎｙｌｕｒｅａ-ｔｒｅａｔｅｄ ｐａｔｉｅｎｔｓ' Ｄｉａｂｅｔｅｓ Ｃａｒｅ Ｖｏｌ．２７， Ｎｏ．１１, 2004, ｐ．２６２８-３５
JPN5008012862; 'ＥＸＥＮＡＴＩＤＥ： ＡＣ ２９９３， ＡＣ００２９９３， ＡＣ２９９３Ａ， ＥＸＥＮＤＩＮ ４， ＬＹ２１４８５６８' ＤＲＵＧＳ ＩＮ Ｒ ＆ Ｄ Ｖ５ Ｎ１, 2004, Ｐ３５-４０, ＡＤＩＳ ＩＮＴＥＲＮＡＴＩＯＮＡＬ
JPN7011001837; Ａｍｙｌｉｎ Ｐｒｅｓｓ Ｒｅｌｅａｓｅ , 2004
Attorney, Agent or Firm:
Mitsuo Tanaka
Yamasaki 宏
Takeshi Sato
Yamasaki 宏
Takeshi Sato
Previous Patent: THERAPY FOR α-GALACTOSIDASE A DEFICIENCY
Next Patent: IMMUNOSTIMULATORY VIRAL RNA OLIGONUCLEOTIDES
Next Patent: IMMUNOSTIMULATORY VIRAL RNA OLIGONUCLEOTIDES